BUSINESS
RIL: Bandwidth of technology investors expands with General Atlantic; Deleveraging on track
First, Facebook, then Vista and Silver Lake, and now General Atlantic. Jio continues to be a big draw for technology investors. The zero-debt goal for RIL has just got more fuel.
BUSINESS
Tata Consumer: Are all the positives priced in?
BUSINESS
Godrej Consumer Q4FY20: All hopes pinned on health and hygiene
BUSINESS
Sequent Scientific Q4: Ownership change can accelerate US plans
BUSINESS
Sequent Scientific: Private equity buyout to remove non-operational risk of pledged shares
BUSINESS
Solara Active Q4: gears up for shift in pharma production from China
BUSINESS
Marico Q4: Portfolio focus on essentials a positive, accumulate on declines
BUSINESS
Laurus Labs Q4: Improving product mix and strong execution drive growth
BUSINESS
Atul Q4: Pharma and agrochem to lead the way
BUSINESS
HUL Q4: Disappointing results, but crisis track record justifies premium valuations
BUSINESS
Reliance's rights issue: Shot in the arm for debt reduction efforts; zero debt target in sight
BUSINESS
Fed April meet: Liquidity backstop to remain till sustained economic recovery
BUSINESS
Aarti Industries: Well-positioned to capture shift in chemical supply chain
BUSINESS
Facebook-Jio deal | Will it help RIL deleverage and re-rate?
Our back-of-the-envelope calculations suggest net debt can decrease by 80 percent if the inflows from the deals with Facebook, Aramco and BP are used to deleverage.
BUSINESS
The Facebook deal is a huge positive for RIL
Our back-of- the- envelope calculations suggest that net debt can decrease by 80 percent if the inflows from the deals with Facebook, Aramco and BP are used to deleverage.
BUSINESS
US FDA tailwind: Structural or situational?
BUSINESS
Pharma companies that can benefit from the demand for complex respiratory drugs
BUSINESS
Diamonds in the Dust: Why ITC presents a value-buying opportunity
BUSINESS
The global stimulus bazooka – Why market downside may be limited
BUSINESS
Marico Q4 update: Skewed growth in food portfolio to sustain
Stock trades at a sharp discount to large caps such as HUL, Dabur, and Britannia
BUSINESS
COVID-19: Which pharma companies can benefit from the export ban relaxation?
While there is a partial relaxation in exports of Hydroxychloroquine, the potential first line of treatment for COVID patients, the main question is the ability to meet domestic needs
BUSINESS
HUL's Horlicks brand buy to save operating cash for better use
We continue to see substantial scope for synergy benefits
BUSINESS
COVID-19 | Supply chain disruptions: The challenges ahead for India Inc
BUSINESS
Lessons for India from China’s stimulus measures
